TenX Keane Acquisition Merger with Citius Pharmaceuticals Oncology Subsidiary to Form Citius Oncology, Inc.
August 12, 2024
TenX Keane Acquisition is merging with Citius Pharmaceuticals’ wholly owned oncology subsidiary to create a new publicly traded company, Citius Oncology, Inc. (expected Nasdaq ticker CTOR), with Citius Pharma retaining majority control (about 90%). The transaction is positioned to support commercialization of LYMPHIR and exploration of additional targeted oncology assets.
- Buyers
- TenX Keane Acquisition
- Targets
- Citius Oncology, Inc., Citius Pharmaceuticals’ wholly owned oncology subsidiary
- Sellers
- Citius Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Location
- New Jersey, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.